Skip to content

Released May 6, 2024, before the open

10-Q filed May 6, 2024, 36 days after period end · 0001628280-24-020455

Q1 2024 · 10-Q
Revenue$5.05M−4.9% vs Q1 2023−12.5% vs Q4 2023
Net Income-$25.02MN/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.59N/M vs Q1 2023no prior Q4 2023 on file
Operating Income-$28,194,000N/M
Operating Cash Flow-$29,345,000N/M
Free Cash Flowderived-$29,446,000N/M
Margins · derived
Operating margin-558.3%+69.3 pt vs Q1 2023
Net margin-495.4%+78.9 pt vs Q1 2023

What the release said

The release

Same quarter

MetricQ1 2024Q1 2023Q1 2022Q1 2021
Revenue$5.05M$5.31M$3.92M$286.00K
Net Income-$25.02M-$30.49M-$26.91M-$22.99M
EPS Diluted-$0.59-$0.73-$0.65-$0.62

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR